ERBB2 and head and neck squamous cell carcinoma: Rosewell et al. established a construct encoding a PD-L1-blocking antibody and IL-12p70 binary lysing adenovirus (CAd), and local treatment combined with CAd12_PD-L1 and systemic HER2 CAR-T cell infusion in an HNSCC xenograft model improved survival to > 100 days [383].